News

ASCO 2026 data show daraxonrasib doubles survival in pancreatic cancer. MSK’s Mary Larsen discusses oral adherence and managing signature side effects.

Susan Rux, PhD, discusses why new nurses leave oncology and how improved communication and teamwork can stabilize the healthcare workforce.

CIBMTR data shows manageable toxicity and outpatient potential for liso-cel in R/R MCL, emphasizing the vital role of nursing vigilance and education.

Non-CME PER® Podcast

Dan Silver, PA-C, discusses proactive strategies for managing treatment-related erectile dysfunction and penile rehabilitation in prostate cancer.

A European survey at EHA 2026 finds nurses central to multiple myeloma care but facing training gaps and severe shortages that limit patient outcomes.

Deanna Lewis, PA-C, explores how reframing communication as clinical infrastructure fosters trust, psychological safety, and innovation in oncology.

Kilan C. Ashad-Bishop details how chronic heat impacts oncology treatment adherence, hydration, and financial security for patients.

FDA approves capivasertib with abiraterone for PTEN-deficient mAPMN/S prostate cancer, requiring specific nursing education on intermittent dosing.

Larry Bilbrey of Tennessee Oncology explains how AI scribes reduce documentation burden and burnout while improving patient-provider engagement.

Oncology nurses can advocate for safe antacid use to prevent unnecessary therapy and optimize outcomes.

FDA approved belzutifan plus pembrolizumab for adjuvant clear cell renal cell carcinoma at high risk of recurrence following nephrectomy.

Michael Adashek, DO, explores why oncology providers must prioritize cascade testing to protect patients’ families from hereditary cancer risks.

Discover how oncology nurses can make a profound impact beyond the bedside by registering as stem cell and bone marrow donors to save lives.

Celebrating 25 years, Dana-Farber’s Cantor Center integrates oncology nursing science into clinical practice to improve patient quality of life.

New research finds extreme heat causes cancer patients to skip appointments and reduce activity, highlighting a need for clinical heat-risk planning.

Experts discuss how body image, fatigue, and shifting relationship roles impact sexual health and intimacy for patients undergoing cancer care.

Dr. Loren Rourke discusses how GLP-1s may impact breast cancer risk by reducing adipose tissue-derived estrogen and chronic metabolic inflammation.

Olympic legend Shannon Miller reflects on her 15-year ovarian cancer journey and why oncology nurses are the key to breaking patient silence.

UC Irvine researchers link ADCs to severe neutropenia, urging oncology nurses to prioritize proactive monitoring and care for at-risk patients.

Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC.

Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.

ASCO 2026 research highlights GLP-1 medications as a potential breast cancer prevention tool, showing a 30% risk reduction in retrospective analysis.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

HR20013 plus dexamethasone improves delayed emesis control and daily functioning for patients on moderately emetogenic chemotherapy in the phase 3 PROTECT trial.